课题基金 / 基金详情

ISOLATION AND CHARACTERIZATION OF CELL CYCLE CHECKPOINT PROTEINS

ISOLATION AND CHARACTERIZATION OF CELL CYCLE CHECKPOINT PROTEINS
细胞周期检查点蛋白的分离和表征
批准号:
8363799
负责人:
FRANK PATRICK MCCORMICK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2012-05-31

项目摘要

项目成果

FRANK PATRICK MCCORMICK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The mitotic spindle assembly checkpoint (SAC) is the only known checkpoint in mitosis. The SAC is composed of complex multi-signal transduction pathways that promote the proper segregation of chromosomes during cell division. As such, defects in the SAC result in chromosome instability (CIN), a hallmark of cancer. Of clinical importance, apoptosis caused by mitotic catastrophe depends on the activation of SAC. However, our knowledge of SAC signaling is far from complete, and the functional cross-talk between SAC activation and the induction of mitotic apoptosis is poorly understood. This makes it difficult to explain the mechanism by which cancer cells respond or become refractory to anti-mitotic drugs, e.g. taxol, that induced spindle-damage or mitotic catastrophe. Therefore, it is highly important to understand both the molecular mechanism by which SAC (i) controls proper chromosome segregation to maintain chromosome stability during cell division and (ii) elicits an apoptotic response in mitosis to anti-mitotic cancer therapeutic drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biodesy Delta System for San Francisco Bay Area Region
New Ways of Targeting K-Ras
New Ways of Targeting K-Ras
New Ways of Targeting K-Ras
海外基金